当前位置: X-MOL首页SCI期刊查询及投稿分析系统 › Drug Safety杂志
Drug Safety
基本信息
期刊名称 Drug Safety
DRUG SAFETY
期刊ISSN 0114-5916
期刊官方网站 https://www.springer.com/40264
是否OA No
出版商 Adis International Ltd
出版周期 Monthly
文章处理费 登录后查看
始发年份 1986
年文章数 96
影响因子 4.0(2023)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 PHARMACOLOGY & PHARMACY 药学2区
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 公共卫生、环境卫生与职业卫生2区
TOXICOLOGY 毒理学2区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 7.6 1.204 1.277
Medicine
Pharmacology (medical)
44/272 84%
Pharmacology, Toxicology and Pharmaceutics
Toxicology
23/133 83%
Pharmacology, Toxicology and Pharmaceutics
Pharmacology
81/313 74%
补充信息
自引率 7.5%
H-index 115
SCI收录状况 Science Citation Index Expanded
官方审稿时间 登录后查看
网友分享审稿时间 数据统计中,敬请期待。
接受率 登录后查看
PubMed Central (PMC) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0114-5916%5BISSN%5D
投稿指南
期刊投稿网址 https://www.editorialmanager.com/drsa
收稿范围
Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:   

Overviews of contentious or emerging issues. 
Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. 
In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. 
Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
Editorials and commentaries on topical issues.
收录体裁
投稿指南 https://link.springer.com/journal/40264/submission-guidelines
投稿模板
参考文献格式
编辑信息

Editor (Adis International Limited, Auckland, New Zealand):

Nitin Joshi

Editorial Board:

G.C. Alexander, John Hopkins School of Public Health, Baltimore, MD, USA

L. Azoulay, McGill University, Montreal, QC, Canada

B. Bannwarth, Hospital Pellegrin-Tondu, Bordeaux, France

J. Barnes, University of Auckland, Auckland, New Zealand

D.W. Bates, Harvard Medical School, Boston, MA, USA

F.M.C Besag, National Health Service, Bedford, England

N. Buckley, University of Sydney, Sydney, NSW, Australia

R.O. Day, University of New South Wales, Darlinghurst, NSW, Australia

F. De Ponti, University of Bologna, Bologna, Italy

A.N.O. Dodoo, University of Ghana Medical School, Accra, Ghana

I.R. Edwards, Gothenburg, Sweden

A.C.G. Egberts, Utrecht University, Utrecht, the Netherlands

S.J.W. Evans, London School of Hygiene and Tropical Medicine, London, England

A. Figueiras, University of Santiago de Compostela, Santiago de Compostela, Spain

J. Gagne, Harvard Medical School, Boston, MA, USA

S.A. Goldman, Stephen A Goldman Consulting Services, Morris Plains, NJ, USA

A.J. Gordon, Pharmaceutical Consultant, Greenwich, CT, USA

S. Hägg, Linköping University, Linköping, Sweden

K.Y. Hartigan-Go, Asian Institute of Management, Manila, Philippines

L. Howes, Griffith University, Southport, QLD, Australia

D. Hunt, MRC Institute of Genetics and Molecular Medicine, Edinburgh, Scotland

S. Jick, Boston University School of Public Health, Lexington, MA, USA

S. Krähenbühl, University Hospital Basel, Basel, Switzerland

K. Kubota, NPO Drug Safety Research Unit Japan, Tokyo, Japan

J.-R. Laporte, Fundació Institut Català de Farmacologia, Barcelona, Spain

D. Layton, QuintilesIMS, and University of Portsmouth, Portsmouth, England

H. Le Louet, Henri Mondor University Hospital, Paris, France

J.H. Lewis, Georgetown University School of Medicine, Georgetown, DC, USA

M. Lindquist, The Uppsala Monitoring Centre, Uppsala, Sweden

Y.K. Loke, University of East Anglia, Norwich, England

C.R. Meier, University of Basel, Basel, Switzerland

R. Meijboom, University of Utrecht, Utrecht, the Netherlands

P.G.M. Mol, University Medical Center Groningen, Groningen, the Netherlands

J.-L. Montastruc, Université Toulouse III Paul Sabatier, Toulouse, France

N. Moore, Universite de Bordeaux, Bordeaux, France

G.N. Norén, The Uppsala Monitoring Centre, Uppsala, Sweden

M. Pirmohamed, University of Liverpool, Liverpool, England

R.L. Savage, New Zealand Pharmacovigilance Centre, Dunedin, New Zealand

N. Shah, Stanford University School of Medicine, Stanford, CA, USA

R.R. Shah, Rashimi Shah Consultancy, Ltd., Gerrards Cross, England

S. Shakir, Drug Safety Research Unit, Southampton, Hampshire, England

N. Shear, University of Toronto, Toronto, ON, Canada

O. Spigset, St Olav's University Hospital, Trondheim, Norway

N.P. Tatonetti, Columbia University, New York, NY, USA

G. Trifirò, University of Messina, Messina, Italy

M. Tuccori, University Hospital of Pisa, Pisa, Italy

E.P. van Puijenbroek, Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands

L.V. Wilton, Southampton, England

I.C.K. Wong, UCL School of Pharmacy, London, England

L. Zhang, Beijing University of Chinese Medicine, Beijing, China


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug